CDC42BPA and ovarian carcinoma: Consistent with these observations, TCGA data revealed gene amplifications of Cdc42BPA, Cdc42BPB, and Cdc42BPG or their upstream regulator Cdc42 in 96/584 (16.4%) of ovarian cancer cases [45,46] (Figure 5A,B).